|Day's Range||2,726.46 - 2,731.20|
|52 Week Range||2,532.69 - 2,940.91|
In October, investors started to get a sense of what the market will be like in 2019 — more concern, more volatility, and more talk about the end of the cycle.
Paul Tudor Jones, a hedge-fund luminary, says he’s stress-testing his portfolio of corporate debt because he expects a tumultuous road ahead for that market segment.
Wall Street was set to open lower on Monday as shares of Apple and its suppliers were hit by ongoing concerns of slowing demand for iPhones, while conflicting signals of a potential truce in the China-U.S. trade dispute added to market jitters. Shares of Apple Inc fell 1.8 percent in premarket trading after the Wall Street Journal reported the company has cut production orders in recent weeks for all three iPhone models launched in September.
Cosmo Pharmaceuticals N.V.'s Aries Pharmaceuticals, Inc. said early Monday that its Aemcolo medication has been approved in the U.S. for traveler's diarrhea, making it the first antibiotic approved for the condition in more than a decade, according to the company. The product, a formulation of the antibiotic rifamycin that is delivered to the colon for traveler's diarrhea caused by E. coli, will be available in pharmacies in the first quarter of next year. You can probably guess what the symptoms of traveler's diarrhea are; the condition isn't usually serious when it happens to healthy adults but "can certainly make for an unpleasant trip," according to the Centers for Disease Control and Prevention. Cosmo Pharmaceuticals shares were up 4% on Monday; shares have dropped nearly 6% over the last three months, compared with a 4% drop in the S&P 500 and a 1% decline in the Dow Jones Industrial Average .
Treasuries declined, the dollar steadied and gold fell. Telecommunications shares helped support the Stoxx Europe 600 Index, though the gauge was held back by a plunge in Renault SA following misconduct allegations against the carmaker’s leader. Equities posted modest increases in Tokyo, Hong Kong, Shanghai and Taiwan.
French carmaker Renault saw its share price tank after partner Nissan accused its chairman of serious misconduct and announced plans to oust him. NISSAN BOSS: Nissan Motor Co.'s chairman Carlos Ghosn is to be dismissed after the company said an internal investigation found he under-reported his income by millions of dollars and engaged in other "significant misconduct." The Yokohama-based company, one of the world's largest automakers, said the violations were discovered during an investigation over several months that was instigated by a whistleblower. The announcement came after Japanese stock markets had closed so there was no impact on Nissan's share price.
In September, energy services including the electricity and utility (piped) gas service, had a relative importance of 3.4% to the US CPI-U (Consumer Price Index for All Urban Consumers), according to the Bureau of Labor Statistics. From 2003 to 2004, gas (piped) and electricity had a relative importance of 4.2% to the US CPI-U.
Compass Minerals International Inc. said Monday Chief Executive Fran Malecha will step down, effective immediately, after nearly six years in the role. The essential minerals company said the decision was made by mutual agreement between the board of directors and Malecha. The company named Lead Independent Director Dick Grant interim CEO until a permanent CEO is named. Malecha joined Compass Minerals as CEO in January 2013. "The board remains committed to achieving best-in-class operational efficiency in our Salt business to maximize its cash generating capabilities and investing in our higher-growth, global Plant Nutrition business," Grant said. We are now moving forward with a keen focus on execution in order to ensure we can drive value from these investments and deliver sustainable, long-term value creation for our shareholders." The stock, which was still inactive in premarket trade, has tumbled 27% year to date, while the S&P 500 has gained 2.3%.
Shares of Babcock & Wilcox Enterprises Inc. rose 4.3% in premarket trade Monday after the energy and environmental technologies company said Chief Executive Leslie Kass is leaving the company after just 9 months in the role "to pursue other opportunities." The company has named Kenny Young as its new CEO, effective immediately. Young was previously president of B. Riley Financial Inc. Separately, the company said Lou Salamone, most recently with CityMD, was named executive vice president of finance, with the expectation that he will become chief financial officer, to succeed current interim CFO Joel Mostrom. "The executive changes put in place a proven leadership team with a combination of turnaround expertise and power industry experience and are intended to unlock value from B&W's various segments and lead to increased shareholder returns," the company said in a statement. the new management team was granted equity awards that will begin to vest when the price of B&W's stock reaches $2.25, which is 162% above Friday's closing price of 86 cents. The stock has plunged 85% year to date through Friday, while the S&P 500 has gained 2.3%.
Futures for Canada's main stock index was little changed on Monday amid conflicting signals of a potential truce in the U.S.-China trade dispute. Last week, U.S. President Donald Trump said he might not ...
Merck KGaA and Pfizer Inc. said early Monday that the cancer immunotherapy avelumab did not meet the primary endpoints of a phase 3 ovarian cancer trial. The trial, JAVELIN Ovarian 200, tested avelumab both alone and in combination with chemotherapy. It specifically focused on individuals with platinum-resistant or -refractory ovarian cancer, or cancers that did not respond to prior chemotherapy treatment, "a population known to have disease that is challenging to treat; as such, this group of patients in typically not included in Phase 3 ovarian cancer trials," Dr. Chris Boshoff, Pfizer's senior vice president and head of immuno-Oncology, early development and translational oncology, said. "The results speak to the significant challenges these women face." Another Merck and Pfizer trial of avelumab, in a type of lung cancer, also did not meet its primary endpoint earlier this year. The drug is being tested in several other types of cancer, with roughly 17 total clinical trials ongoing, according to Pfizer's drug pipeline. Both U.S.-listed Merck KGaA and Pfizer shares were inactive in Monday premarket trade. Merck KGaA shares have surged 8.8% over the last three months and Pfizer shares have risen 3.4%, compared with a nearly 4% drop in the S&P 500 and a 1% decline in the Dow Jones Industrial Average .
World shares struggled higher on Monday amid conflicting signals of a potential truce in the China-U.S. trade dispute, while the Federal Reserve's new-found concerns over the global economy sapped the dollar. Renault's shares crashed more than 10 percent as it and Nissan's joint chairman, Carlos Ghosn, was arrested in Japan for financial misconduct. The sector's gloom was further compounded by a 10 percent slump in VW's global October numbers, and with Wall Street futures dithering either side of flat in New York overall sentiment was starting to backslide again.
World shares struggled higher on Monday amid conflicting signals of a potential truce in the China-U.S. trade dispute, while the Federal Reserve's new-found concerns over the global economy sapped the dollar. Renault's shares crashed more than 10 percent as it and Nissan's joint chairman, Carlos Ghosn, was arrested in Japan for financial misconduct. The sector's gloom was further compounded by a 10 percent slump in VW's global October numbers, and with Wall Street futures dithering either side of flat in New York (ESc1) overall sentiment was starting to backslide again.